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Interpretation of eBV infection in 
pan-cancer genome considering 
viral life cycle: LieB (Life cycle of 
epstein-Barr virus)
Hyojin song  1,2, Yoojoo Lim3, Hogune Im4, Jeong Mo Bae  5, Gyeong Hoon Kang5, 
Junhak Ahn6,7, Daehyun Baek6,7, Tae-You Kim3, Sung-Soo Yoon1,3 & Youngil Koh2,3
We report a novel transcriptomic analysis workflow called LiEB (Life cycle of Epstein-Barr virus) to 
characterize distributions of oncogenic virus, Epstein-Barr virus (EBV) infection in human tumors. We 
analyzed 851 The Cancer Genome Atlas whole-transcriptome sequencing (WTS) data to investigate 
EBV infection by life cycle information using three-step LiEB workflow: 1) characterize virus infection 
generally; 2) align transcriptome sequences against a hybrid human-EBV genome, and 3) quantify 
EBV gene expression. Our results agreed with EBV infection status of public cell line data. Analysis in 
stomach adenocarcinoma identified EBV-positive cases involving PIK3CA mutations and/or CDKN2A 
silencing with biologically more determination, compared to previous reports. In this study, we found 
that a small number of colorectal adenocarcinoma cases involved with EBV lytic gene expression. 
Expression of EBV lytic genes was also observed in 3% of external colon cancer cohort upon WTS 
analysis. Gene set enrichment analysis showed elevated expression of genes related to E2F targeting 
and interferon-gamma responses in EBV-associated tumors. Finally, we suggest that interpretation of 
EBV life cycle is essential when analyzing its infection in tumors, and LiEB provides high capability of 
detecting EBV-positive tumors. Observation of EBV lytic gene expression in a subset of colon cancers 
warrants further research.
Several types of human cancers involve the infection of oncogenic viruses within the host genome. Data indi-
cate that 10–15% of human cancers are caused by infection with several types of human viruses1. Various DNA 
viruses, such as human papillomavirus, hepatitis B virus, human herpesvirus 8, and Epstein-Barr virus (EBV), 
and RNA viruses, such as human T-cell lymphotropic virus type 1 and hepatitis C virus, are known to cause 
cancer in humans2. The replication of these DNA and RNA viruses into the host (human) genome via inser-
tional mutagenesis can trigger carcinogenesis due to the effects of virus-encoded elements and host immune 
deregulation3.
EBV (also known as human herpesvirus 4) contributes to the development of human cancers of epithelial cell, 
mesenchymal cell, and lymphocytic origin. Despite the prevalence of EBV in cancers, the biological impact of 
EBV lytic gene expression in cancers is not clearly determined yet. We, therefore, aim to identify EBV expression 
in cancers and understand how EBV expression is related to the biological signature of cancers. Under certain 
conditions, EBV infection can lead to the development of cancer, and this process is closely related to the life cycle 
of EBV (i.e., its latent and lytic stages)4,5. In fact, EBV viremia is present in 14% of healthy populations6. And the 
infection is asymptomatic and remains latent for a long period, with the virus persisting as episomes in infected 
B cells7 without causing disease8,9 in 90% of EBV-infected adults. By contrast, EBV carriers who experience lytic 
EBV infection frequently develop the infection-related disease, including cancers10,11 and autoimmune diseases12. 
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The lytic replication cycle begins when the early transcription factors (TFs) are induced; viral promoters acti-
vated by the TFs facilitate the formation of the initiation complex, which is composed of six viral gene products: 
BMRF1, BSLF1, BBLF4, BBLF2/3, BALF5, and BALF213,14. Once EBV-infected cells enter the lytic cycle, lytic 
antigens are expressed abundantly and trigger cell proliferation15.
The advent of next-generation sequencing (NGS) techniques and recent advancements in computational 
methods have greatly increased understanding of viral metagenomics. Along with shotgun metagenomics tech-
niques, such as nanopore sequencing16,17, improvements in the analytic pipeline brought about by whole-genome 
sequencing (WGS) and WTS have enabled detailed analyses of viral genomes in human samples. For example, 
Cao et al. demonstrated differences in viral infection status between normal and cancerous tissue using VirusScan, 
a novel algorithm that could help further delineate virus-associated carcinogenesis mechanisms18. Metagenomics 
approaches have also broadened knowledge regarding the pathobiology of EBV-related cancers. EBV-associated 
cancers are known to have a distinct mutational profile compared with EBV-negative cancers19. Specifically, The 
Cancer Genome Atlas (TCGA) Research Group revealed that EBV-positive stomach cancers are enriched with 
PIK3CA mutations, extensive DNA methylation, and programmed-death ligand 1/2 (PD-L1/L2) expression20.
In regard to the biological impact of EBV infection in human cancer19, entrance into the EBV lytic cycle begins 
upon differentiation of B lymphocytes towards plasma cells21 and often contributes to EBV-associated tumors22. 
In other words, it is imperative to reflect EBV life cycle information when detecting EBV-associated tumors. 
We, therefore, sought to analyze NGS data from the perspective of the EBV life cycle considering the correlation 
between the lytic EBV stage and human cancers. Combining current knowledge regarding the genes related to 
each EBV stage with abundant WTS/WGS data, we analyzed the correlation between EBV lytic genes and the 
human genome in cancer cases. We hypothesized that in addition to viral infection, the pattern of gene expres-
sion related to the viral stage is important in virus-associated carcinogenesis. Hence, in this study, we examined 
both virus infection status and EBV gene expression pattern using TCGA WTS data. Here, we demonstrate the 
impact of EBV reactivation characterized by lytic phase gene expression as well as the distribution of EBV infec-
tion. From this study, we first established our internal workflow to detect EBV infection and quantify viral gene 
expression. By using our workflow, we also found out that EBV expression in a small proportion of colon cancers.
Results
Detection of EBV infection. We investigated 851 TCGA WTS samples involving 23 cancer types to detect 
EBV infection by employing our three-step LiEB workflow (Fig. 1). We first identified the 286 infection-pos-
itive samples (33.61%) using VirusSeq (Fig. 2a). Then these EBV-positive samples identified using VirusSeq 
were mapped against the four EBV strains (GenBank accession: AJ507799, AY961628, AG876, DQ279927, and 
M80517M75989) using STAR approach; 88 WTS samples (10.34%) were then distinguished to selectively contain 
sequences aligned against the hybrid transcriptome. As a next step, we employed the RSEM algorithm, and RSEM 
analysis indicated expression of EBV latent and lytic genes in 78 samples. Since these samples are identified to 
have any expression of the whole set of 135 EBV genes, we selected 46 of 78 samples by sorting out according to 
the expression of the 23 gene products (13 lytic and 10 latent genes) (Supplementary Table S2). Finally, we could 
classify 46 EBV-positive samples, among which 39 were sub-classified as expressing EBV lytic genes.
Quantification of EBV-related gene expression. Examining the STAR-aligned reads against the EBV 
genome, we quantified the expression of both EBV latent (Fig. 2b) and lytic (Fig. 2c) genes by calculating tran-
script abundance; prior to the identifying the expression of EBV genes related to its life cycle, we quantified the 
overall expression of EBV genes belong to its viral genome (Supplementary Fig. S3). As a well-known EBV-related 
cancer23,24, the proportion of EBV-expressing samples in STAD was high (47X%, 17/36). Unexpectedly, we found 
a proportion of EBV lytic gene expressing cases in colorectal cancers (39%, 24/61): colon adenocarcinoma 
(COAD) and rectal adenocarcinoma (READ) (Fig. 2c). In summary, we could find EBV lytic gene expressing 
cases both in upper and lower gastrointestinal cancers (COAD, READ, and STAD).
In specific, three EBV lytic genes were mainly expressed in the colorectal cancer samples: 1) BZLF1, encoding 
an early transcription factor; 2) BMRF1, encoding a DNA polymerase processivity factor25, and 3) BALF2, encod-
ing an EBV single-stranded DNA-binding protein15. Since these three lytic genes were dominantly expressed in 
STAD, we adduce that enrichment of EBV lytic genes in COAD is convincing.
In silico validation using cell line WTS data. We applied our three-step LiEB approach in cell line WTS 
data (Supplementary Fig. S4a and b) to validate our algorithm. As a result, we could clearly dichotomize cell lines 
regarding EBV status. EBV-positive cell lines (MP-1, Raji, and Akata) exhibited high expression of both lytic and 
latent genes, such as BHRF1, BHLF1, Cp-EBNA2, and LMP-1, whereas two EBV-negative cell line samples (both 
are HCT-116 strains) were not mapped against the hybrid genome (Supplementary Fig. S4), indicating no expres-
sion of EBV genes (Supplementary Fig. S4b). Validation result using cell line WTS data supports the robustness 
and accuracy of detecting EBV of our LiEB workflow.
Accuracy of LiEB method for EBV infection detection in STAD samples. We classified the STAD 
samples into two groups based on the presence of EBV infection by applying LiEB. We compared our results 
with previous data reported by TCGA Networking group20 and by Ding’s group18. As mutational hallmarks of 
EBV related stomach cancer are well described20,26, we analyzed the integrated WXS MAF file to correlate salient 
STAD-related mutation signatures with EBV status. We deemed hallmarks of EBV-related stomach cancer20 as 
mutations in PIK3CA, ARID1A and BCOR genes, PD-L1/2 overexpression, and CDKN2A silencing.
When we compared our result with the previous report by TCGA Networking group20, we could identify five 
more samples (N = 13) with EBV infection than TCGA report (N = 8) which implies the sensitivity of detecting 
EBV lytic expression was raised by 61% with LiEB (concordance rate 86%). In these five additional samples with 
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EBV positivity, hallmarks of EBV infection – either PIK3CA or ARID1A mutation – was observed in three cases: 
STAD_21, STAD_19, and STAD_17 (Table 1). In fact, these five additional samples were also detected as EBV 
positive in recent Li Ding group’s report18.
When we compared our results with Li Ding group’s report, we could observe high concordance between the 
two algorithms (94%). However, there was a discrepancy in two samples between LiEB and Li Ding’s algorithm. 
Two samples (STAD_10 and STAD_1) detected EBV-positive in Li Ding group’s workflow18 seemed not to har-
bor EBV lytic-genes by LiEB workflow. Interestingly, these two samples showed strikingly high expression in 
CDKN2A (669.8 and 349.74 respectively calculated in TPM, Table 1) which is not compatible with characteristics 
of EBV associated STAD. In fact, the EBV positive samples by LiEB workflow showed low CDKN2A expression 
values between 0.55 and 33.4 (in TPM). As described earlier, CDKN2A silencing including gene downregula-
tion27 is a hallmark of EBV associated STAD and this analysis suggests that STAD_10 and STAD_1 may not be 
EBV associated STAD’s at least biologically. In summary, our LiEB workflow detects EBV lytic-positive samples 
more accurately than the previously reported workflows.
External validation of EBV infection in colon cancer cases. To validate EBV lytic gene expres-
sion in colorectal cancer, we analyzed separate 30 colon cancer transcriptome sequencing data collected from 
our institution (SNUH cohort). In SNUH cohort, seven cases showed expression of EBV genes, with one case 
(SNUH_COAD_7) exhibiting comparatively high expression of EBV lytic genes (3% positivity by LiEB) (Fig. 3). 
The results of PCR analyses using the EBNA1 probe correlated well with EBV gene expression in transcriptome 
sequencing data (EBV viral load of case SNUH_COAD_7 was 27,872 copies/mL).
Gene Set Enrichment Analysis (GSEA). In TCGA STAD project, GSEA of EBV-positive samples detected 
using our LiEB workflow demonstrated enrichment in inflammation-related gene sets: Interferon-gamma 
response, Interferon-alpha response, inflammatory response, and Interleukin2-STAT5 signaling. This is in con-
trast to the previous analysis: GSEA results based on the EBV detection by TCGA Networking group showed 
that genes in the Pancreas-beta cells and Estrogen response late gene sets were enriched in EBV-positive samples 
(Fig. 4a). We could easily conclude that GSEA result based on LiEB is more biologically relevant than previ-
ous analysis (Fig. 4b). In addition, it should be noted that E2F related gene expression was enriched in EBV 
positive cancers when analyzed by LiEB. E2F is a factor that is crucial for cancer development in virus-related 
oncogenesis28.
Figure 1. Workflow of the three-step EBV in silico detection algorithm. We examined 851 WTS samples 
covering 23 cancer types from TCGA database. Our workflow (LiEB) involves three steps to detect EBV-positive 
samples: (1) detection of viral infection; (2) alignment against a hybrid genome; (3) quantification of EBV gene 
expression.
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Discussion
Viral infections in humans can lead to carcinogenesis resulting from dysfunction in the host immune system. 
And EBV is closely related to human cancers originating from epithelial cells, lymphocytes, and mesenchymal 
cells19,20. According to the “Hit and Hide” theory suggesting that EBV evades the host immune system by remain-
ing dormant in cells, the lytic infection can trigger the induction and maintenance of EBV-positive cancers29,30. In 
addition, the expression of EBV lytic gene products can induce the production of growth factors and oncogenic 
cytokines31 that in turn contribute to carcinogenesis. Hence, in the analysis of EBV-related cancers, the life cycle 
of EBV including lytic gene expression should be considered. This is the starting point where we developed LiEB 
algorithm. In this study, infection of EBV genomic sequences was identified in ~10% of cancers mostly originat-
ing from epithelial cells and only half of these cases (~4.6%) involve EBV lytic gene expression.
We could confirm the accuracy of LiEB in various aspects. First is through mutation profiling of TCGA STAD 
dataset. We observed a stronger association between PIK3CA mutation and CKNA2A silencing with EBV infec-
tion than the previous reports. It is well known that both of PIK3CA mutation and down-regulation of CDKN2A 
is a hallmark of EBV associated tumor1. Second, based on GSEA results, we confirmed that our LiEB workflow 
detects more biologically meaningful EBV-related tumors as the EBV-positive sets were heavily enriched with 
Figure 2. (a) Proportion of EBV-positive samples among 23 cancer types examined. Each bar represents 
the percentage of samples in which one or more mapped read was detected for each of the four EBV strains 
(HHV4_wt, HHV4_GD1, HHV4_AG876, and EBV_artifactual_join) examined. Note that we did not include 
READ in the further analysis set due to an insufficient number of sample sets (N = 7), although this cancer 
type shows a high proportion of EBV infection in this figure. (b,c) Proportion of samples expressing EBV latent 
and lytic genes among 23 cancer types examined. Each stacked bar indicates the percentage of samples of each 
cancer type expressing EBV latent (b) and lytic (c) genes. Colors represent each TCGA cancer project.
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gene set related to inflammation and E2F targeting. Inflammation is a central feature of virus-associated cancers. 
When cells are infected, inflammatory signaling is activated and inflammatory cytokines recruit various types of 
immune cells (e.g., eosinophils, monocytes, mast cells, and T cells) that target infectious viral antigens32. We could 
only observe the enrichment of inflammatory pathways from GSEA when we classified EBV status using LiEB, 
and not by using TCGA Network analysis. Also, E2F is a transcription factor that regulates carcinogenesis in case 
of virus-related cancers28,33.
We employed a three-step viral infection detection algorithm in LiEB. What was an unexpected finding in 
our study is that we found a small proportion of EBV-positive samples in colorectal cancers. Two TCGA sam-
ples (involving colon and rectal adenocarcinoma) exhibited expression of EBV lytic genes (BZLF1, BMRF1, 
and BALF2), analogous to that observed in EBV-positive stomach cancer samples. We identified additional 
EBV-positive colon cancer in SNUH cohort, which supports that EBV may play a role in a small number of colon 
cancers. Moreover, viral load analysis result using quantitative PCR was concordant with the expression of EBV 
genes detected using LiEB. (Supplementary Table S2). However, we could not observe a definite signal of EBV 
infection when tested by EBV in situ hybridization (ISH). EBER ISH results in seven EBV-gene expressing (either 
lytic- or latent-positive) cases showed a few stained tumor-infiltrating lymphocytes between tumor glands (data 
not shown). It should be noted however that, ISH is an inferior method to NGS in detecting EBV infection34. 
EBER-ISH is capable of detecting EBV positivity when tumors contain a certain amount of EBV-aligned reads.
STAD_id
EBV 
(TCGA)
EBV_
Lytic 
(Hsong)
EBV (Li 
Ding)
TPM 
(CDKN2A) CDKN2A PIK3CA ARID1A BCOR RHOA
TPM 
(PDL1)
TPM 
(PDL2)
STAD_13 1 1 1 3.97 0 Missense Nonsense Splice_Site 0 309.51 14
STAD_28 1 1 1 4.59 Missense Missense fsDEL, ifDEL, Nonsense 0 0 125.1 9.86
STAD_24 1 1 1 18.99 0 Missense 3′UTR 0 Missense 29.19 2.84
STAD_11 1 1 1 26.12 Missense Missense fsDEL 0 0 19.25 2.71
STAD_34 1 1 1 33.4 0 0 ifDEL 0 0 7.58 3.28
STAD_27 1 1 1 6.48 0 Missense Nonsense 0 0 3.74 3.06
STAD_31 1 1 1 0.55 0 fsDEL 0 0 1 0.19
STAD_8 1 1 1 2.23 0 0 0 0 6.37 3.96
STAD_21 0 1 1 6.25 0 Missense fsDEL, Splice_Region Missense 0 4.06 2.74
STAD_19 0 1 1 7.83 0 Missense, ifDEL Missense 4.78 1.28
STAD_17 0 1 1 1.45 0 Missense ifDEL 0 3.74 1.37
STAD_3 0 1 1 17.4 0 0 0 0 0 2.94 2.8
STAD_25 0 1 1 13.73 0 0 0 0 0.95 0.57
STAD_10 0 0 1 669.8 fsDEL, ifDEL 0 ifDEL 0 0 3.81 1.59
STAD_1 0 0 1 349.74 Missense 0 0 Missense 0 6.1 1.25
STAD_32 0 0 0 124.75 0 0 ifDEL 0 0 2.14 2.19
STAD_4 0 0 0 12 0 0 0 0 0 3.65 2.09
STAD_5 0 0 0 12.49 Missense Missense, fsDEL, ifDEL Missense 0 2.82 2.19
STAD_22 0 0 0 2.89 0 0 ifDEL 0 0 3.59 0.38
STAD_16 0 0 0 1.09 0 0 fsINS 0 Missense 1.21 0.25
STAD_2 0 0 0 3.61 0 Missense fsDEL, ifINS 0 2.03 1.21
STAD_6 0 0 0 41.64 0 0 0 0 0 3.14 2.47
STAD_7 0 0 0 44.47 0 Missense Missense, ifDEL 0 0 2.8 2.67
STAD_9 0 0 0 26.12 0 0 ifDEL 0 0 1.48 1.4
STAD_33 0 0 0 183.79 0 0 ifDEL 0 0 5.51 0.99
STAD_14 0 0 0 19.54 0
fsINS, 3′UTR, 
Splice_Site, 
Splice_Region
fsDEL, ifDEL 0 3.13 1.31
STAD_18 0 0 0 160.75 Missense 0 fsDEL, ifDEL Missense 0 2.83 2.27
STAD_36 0 0 0 207.21 Missense, fsDEL, 3′UTR 11.24 3.48
STAD_20 0 0 0 41.25 0 0 3′UTR, ifDEL 0 0 0.58 0.26
STAD_23 0 0 0 29.9 0 0 ifDEL 0 0 0.78 1.11
STAD_15 0 0 0 234.54 Missense 0 0 0 0.39 0.35
STAD_35 0 0 0 42.19 0 0 0 0 0 1.54 1.04
STAD_30 0 0 0 11.78 0 0 ifDEL 0 0 0.17 0.41
STAD_29 0 0 0 11.96 0 0 0 0 0 0.19 0.41
STAD_26 0 0 0 2.36 0 0 ifDEL 0 0 0.83 0.41
STAD_12 0 0 0 2.99 0 0 Missense Nonsense 0 3.36 1.41
Table 1. Significant mutations related to STAD (TCGA)*. *fsINS, Frame_Shift_Ins; fsDEL, Frame_Shift_Del; 
ifDEL, In_Frame_Del; ifINS, In_Frame_Ins.
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Furthermore, we tried to look into noncoding RNAs called miRNAs related to EBV life cycle. Both cellular 
and viral miRNAs regulate gene expression of either host or virus itself and affect regulatory networks as a part of 
the carcinogenic mechanisms35. In particular, cellular miRNAs interact with viral oncoproteins and this biolog-
ical processes influence often enhances the survival of virus-infected cells36,37. Analysis of miRNA expression in 
Figure 3. (a) EBV lytic gene expression and its partial genomic structure. (Left) Thirteen EBV lytic genes were 
classified into three categories according to the sequential processes of the lytic stage: early transcription factors, 
initiation complex genes, and lytic antigens (c.f., the list of lytic genes refers to Draborg, A. H. et al. Clinical and 
Developmental Immunology [2012]). (Right) Heatmap illustrating the expression of EBV lytic genes in three 
types of gastrointestinal cancer types: colon adenocarcinoma (COAD, red), rectal adenocarcinoma (READ, 
blue), and stomach adenocarcinoma (STAD, green). The gradation of blue color indicates the row-scaled 
expression value of each EBV gene. Three annotation bars on STAD samples indicate those that were EBV 
positive as detected by our LiEB workflow and in published preliminary reports: TCGA Network group20 and 
Li Ding group18. (b) Comparison of EBV lytic gene expression in TCGA COAD, READ, and SNUH_COAD. 
Heatmap illustrating the expression of EBV lytic genes in three gastrointestinal cancer cohorts: SNUH colon 
cancer (COAD-SNUH, red), TCGA colon adenocarcinoma (COAD-TCGA, blue), and rectal adenocarcinoma 
(READ-TCGA, green). The gradation of blue color indicates the column-scaled expression value of each EBV 
gene.
Figure 4. Dot plot of enriched pathways determined from GSEA results. Each dot plot demonstrates enriched 
pathways in TCGA (5a) and LiEB (5b) comparison of GSEA results. The size of the dot represents gene count, 
and the color represents the adjusted p-value.
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EBV-positive cell lines (AKBM, C666-1, SNU-719, and Jijoye) revealed that the expression of miRNAs associated 
with EBV lytic cycle varied in terms of latency phases (from latency I to III) (Supplementary Data S5). Because 
there were only latently infected EBV-positive cell lines available for public use, we could indirectly speculate 
how those miRNAs may function in the EBV-infected cells. We identified the expression of viral miRNAs signifi-
cantly associated with EBV reactivation such as miR-BART2, miR-BART18, and miR-BART2010,38, and observed 
that expression of those viral miRNAs was gradually increased upon latency phases from Latency I to III. The 
increased expression of the viral miRNAs in latently-infected cells implicates that the viral latency is established 
and maintained, not contributing to inducing lytic cycle39. In specific, miR-BART20 directly targets lytic switch 
proteins (Zta and Rta), and its expression blocks lytic induction40. Along with the expression of viral miRNAs, we 
also identified expression of cellular miRNA genes involved in EBV reactivation such as miR-155 and miR-200 
family members (miR-200b and miR-429); especially, miR-200 family members are involved in modulating EBV 
lytic reactivation by downregulating ZEB1 and ZEB2 on viral lytic gene product, Zta (also known as BZLF1)41,42. 
Since we observed lower expression of these cellular miRNAs in both Latency I and III, this suggests that the cells 
expressing miR-200 family members may control whether to turn the lytic switch on. From our analysis, hence, 
we support that the expression of those miRNAs, especially ebv-miR-BART20 and hsa-miR-200 family, either 
suppress the induction of lytic cycle43 or is depleted in latently infected B cells42.
In summary, we investigated WTS data in pan-cancer samples to identify cases involving infection with EBV. 
Two major conclusions could be drawn based on the results of this study. First, our LiEB workflow detecting the 
expression of EBV lytic genes provides an indication of biologically important EBV infection in humans, beyond 
simple viral infection. The ability to determine whether the host has entered the lytic or latent stage of the EBV life 
cycle would be significant for preventing severe symptoms or development of cancer by providing personalized 
therapies in advance. Second, we elucidated the EBV gene expression pattern in a small portion of colon cancers, 
and these patterns were analogous to that in stomach cancers.
Conclusively, our findings provide information that brings us closer to a comprehensive understanding of 
EBV infection, especially in cooperation to the EBV lytic stage and EBV-associated carcinogenesis. Furthermore, 
this transcriptomic investigation determining EBV latent and lytic stage might suggest novel clues to understand 
the biological roles of EBV lytic expression in gastrointestinal carcinomas.
Materials and Methods
Input data collection. We used tumor TCGA WTS data for 851 samples covering 23 cancer types 
(Supplementary Table S1). These samples were generated from 827 donors, with the remaining samples derived 
from the same donor with acute myeloid leukemia (AML) and stomach adenocarcinoma (STAD). The data were 
downloaded in raw FASTQ file format, which was appropriate for initiating specialized alignment against the 
sequence of a newly generated hybrid human/EBV genome.
Use of WTS data to detect EBV infection. WTS data was analyzed by using our internally developed 
workflow called LiEB (Life cycle of Epstein-Barr virus), detecting infection and expression of Epstein-Barr virus 
in terms of its lytic/latent life cycle.
Rapid detection of viral infection. VirusSeq was used for rapid detection of viral infection into the human 
genome44. The VirusSeq algorithm utilizes viral genomic sequences currently available on Genome Information 
Broker for Viruses (http://gib-v.genes.nig.ac.jp/) database45. Rough infection of EBV into the human genome was 
estimated using genomic information for four EBV strains (codes in parentheses are GenBank accession): human 
herpesvirus 4, complete wild-type genome (AJ507799); human herpesvirus 4, strain GD1 (AY961628); human 
herpesvirus 4, strain AG876 (DQ279927), and EBV artifactual join (M80517M75989).
Alignment against a human/EBV hybrid reference genome. Spliced Transcripts Alignment to a Reference 
(STAR)46 was performed against a human (GRCh38 assembly)/EBV (type 1 EBV strain) hybrid reference 
genome. Because the genomic sequences of typical EBV type 1 strains contain a site for the splitting of the cir-
cular genome adjacent to the terminal repeats (TRs), it can be challenging to detect LMP2 transcripts located in 
the genome in close proximity to the TRs47; LMP2 encodes LMP2A and LMP2B. However, the inverted genomic 
sequence of Akata cells (an EBV-positive cell line established from a Japanese patient with Burkitt’s lymphoma) 
contains a breakpoint between the BBRF3 and BGLF3 genes instead of near the TRs, making this sequence 
more suitable for detecting LMP2 transcripts48,49. We, therefore, used an “inverted” FASTA format of the Akata 
genome sequence to investigate the infection of EBV genomic sequences. Using the inverted Akata genome as an 
EBV reference genome enabled us to overcome the difficulties associated with both detecting the mapped reads 
against LMP2 transcripts in the alignment procedure and capturing LMP2 mRNA expression for gene expression 
quantification50.
Analysis of EBV-related gene expression. We used the identical reference genome of the EBV type 1 strain 
(chrEBV_Akata_inverted) to quantify the expression of EBV latent and lytic genes by applying RNA-Seq by 
Expectation-Maximization (RSEM) algorithm v1.3.051, calculated as transcripts per million (TPM) values. In 
order to determine the EBV life cycle stage in each tumor examined, we used a list of 135 EBV gene products52 
and calculated the expression in TPM unit for each. In order to more clearly delineate life cycle stage, we exam-
ined a set comprised of 23 EBV gene products15 (Supplementary Table S2) involved in both lytic and latent infec-
tion stages. The resulting data were used to determine whether each EBV-positive sample had entered the lytic 
stage for viral reactivation or was in the latent stage and therefore dormant.
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In silico validation using cell line WTS data. Raw FASTQ files of cell line WTS data were down-
loaded from the NCBI SRA open source (SRA study accession: SRP079984 and SRP107862). Data for known 
EBV-positive lymphoblastoid cell lines (MP-1, Raji, and Akata) and an EBV-negative colorectal cell line (HCT-
116) were used for preliminary external validation of LiEB workflow (see Supplementary Fig. S4a and b).
External validation of EBV infection in different colon cancer samples. WTS data collected from 
30 cases of colon cancer diagnosed at the Seoul National University Hospital (SNUH) were used for external val-
idation (IRB No. 1809-046-971). The infection and expression of EBV-related genes were examined according to 
the LiEB workflow described in both 2) Alignment against a human/EBV hybrid reference genome and Analysis 
of EBV-related gene expression section above. Polymerase chain reaction (PCR) was then performed to validate 
the expression of EBV genes in the colon cancer cohort. The PCR probe was designed to target Epstein-Barr 
nuclear antigen 1 (EBNA1; a nuclear protein expressed in both the latent and lytic stages of EBV infection53) and 
used to determine the number of EBV copies in each sample (i.e., the EBV viral load). We further performed con-
ventional in situ hybridization (ISH) method by using the probe for EBV-encoded small RNA (EBER), to define 
EBV infection status.
Mutation signature profiling. The integrated mutation annotated format (MAF) file for whole-exome 
sequencing (WXS) in the STAD project was download from the Genomic Data Commons data portal, adminis-
tered by the National Cancer Institute; the protected version of the TCGA MAF file is available for use by author-
ized members. In order to verify the correlation between the expression of genes associated with EBV-positive 
STAD (PDL1, PDL2, and cyclin-dependent kinase inhibitor 2A (CDKN2A)) and EBV lytic-positive samples, the 
TPM values of these genes were matched to the STAD samples.
Gene set enrichment analysis (GSEA). To demonstrate the effectiveness of our LiEB workflow, we com-
pared the EBV-positive results from a previous TCGA report20 with the workflow using GSEA. Samples were first 
segregated as either EBV-positive or EBV-negative. Next, we analyzed a set of differentially expressed genes and 
used the output as the GSEA input data (GSEABase R package). As the input gene set for enrichment analysis, we 
used a gene matrix transposed file of hallmark gene sets available from the Molecular Signatures Database collec-
tion website, supported by the Broad Institute (http://software.broadinstitute.org/gsea/msigdb/collections.jsp). 
After GSEA, we utilized the DOSE R package to construct a list of enriched gene sets in the comparison group. In 
this step, two types of GSEA have performed: comparisons between 1) TCGA-positive samples and the remaining 
samples, and 2) our LiEB-positive samples and the remaining samples.
Data Availability
The main datasets used in this study are available from the corresponding authors for reasonable academic pur-
poses. Besides, the datasets used for validation are available on the NCBI SRA and study accessions are mentioned 
in the text where it is used.
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